Dyadic Q2 revenues up

Dyadic’s net loss was $736,204, or $0.02 loss per diluted share, compared to $1.41m, or $0.05 per diluted share, for the same period in 2010.

The company’s loss from operations for the second quarter of 2011 was $624,957, compared to $1.39m for the same period in 2010.

For the six months ended 30 June 2011, the company reported a total revenue of $5.28m, compared to $4.2m for the same period in 2010.

The company has reported net loss of $2.24m or 0.07 loss per diluted share for the six months ended 30 June 2011, as compared to $2.52m or $0.08 loss per diluted share for the same period in 2010.

Dyadic’s loss from operations was $2.02m for the six months of 2011, compared to $2.52m for the same period in 2010.

Dyadic president and CEO Mark Emalfarb said they opened the quarter with first significant research collaboration in biopharmaceuticals with Sanofi Pasteur and EnGen Bio to leverage the company’s C1 technology to produce certain vaccines.

"We closed the quarter with a research, development and license agreement with a major player in the animal feed industry to use C1 to produce new animal feed products," Emalfarb said.

Dyadic is focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.